Evidence map›Paper›PMID 36293042›Full record

ReviewInternational journal of molecular sciences2022

The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH-Future Horizons in NASH Management.

Eleni-Myrto Trifylli, Anastasios G Kriebardis, Evangelos Koustas, Nikolaos Papadopoulos, Melanie Deutsch, Georgios Aloizos, Sotirios P Fortis, Effie G Papageorgiou, Ariadne Tsagarakis, Spilios Manolakopoulos

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Eleni-Myrto TrifylliLaboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, Section of Medical Laboratories, School of Health & Caring Sciences, University of West Attica (UniWA), Ag. Spyridonos Str., 12243 Egaleo, Greece.
Anastasios G KriebardisLaboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, Section of Medical Laboratories, School of Health & Caring Sciences, University of West Attica (UniWA), Ag. Spyridonos Str., 12243 Egaleo, Greece.ORCID 0000-0003-3915-1829
Evangelos KoustasFirst Department of Internal Medicine, 417 Army Share Fund Hospital, 11521 Athens, Greece.
Nikolaos PapadopoulosFirst Department of Internal Medicine, 417 Army Share Fund Hospital, 11521 Athens, Greece.ORCID 0000-0002-8702-1685
Melanie Deutsch2nd Department of Internal Medicine, Hippokration General Hospital of Athens, Medical School, National and Kapodistrian University of Athens, Leof. Vasilissis Sofias Avenue Str., 11527 Athens, Greece.
Georgios AloizosFirst Department of Internal Medicine, 417 Army Share Fund Hospital, 11521 Athens, Greece.
Sotirios P FortisLaboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, Section of Medical Laboratories, School of Health & Caring Sciences, University of West Attica (UniWA), Ag. Spyridonos Str., 12243 Egaleo, Greece.
Effie G PapageorgiouLaboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, Section of Medical Laboratories, School of Health & Caring Sciences, University of West Attica (UniWA), Ag. Spyridonos Str., 12243 Egaleo, Greece.
Ariadne TsagarakisBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Spilios Manolakopoulos2nd Department of Internal Medicine, Hippokration General Hospital of Athens, Medical School, National and Kapodistrian University of Athens, Leof. Vasilissis Sofias Avenue Str., 11527 Athens, Greece.
University of West Attica · GRNational and Kapodistrian University of Athens · GRBeth Israel Deaconess Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is considered the most frequent chronic hepatic disease in the general population, while it is the first cause of liver transplantation in the US. NAFLD patients will subsequently develop non-alcoholic steatohepatitis (NASH), which is characterized by aberrant hepatocellular inflammation with or without the presence of fibrosis. The lack of specific biomarkers and therapeutic strategies makes non-alcoholic steatohepatitis (NASH) management a difficult task for clinicians. Extracellular vesicles (EVs) constitute a heterogenic population of vesicles produced by inward or outward plasma-membrane budding. There is an emerging connection between autophagy EVs production, via an unconventional non-degradative procedure. Alterations in the amount of the secreted EVs and the cargo they carry are also involved in the disease progression and development of NASH. Autophagy constitutes a multistep lysosomal degradative pathway that reassures cell homeostasis and survival under stressful conditions, such as oxygen and energy deprivation. It prevents cellular damage by eliminating defected proteins or nοn-functional intracellular organelles. At the same time, it reassures the optimal conditions for the cells via a different mechanism that includes the removal of cargo via the secretion of EVs. Similarly, autophagy machinery is also associated with the pathogenetic mechanism of NAFLD, while it has a significant implication for the progression of the disease and the development of NASH. In this review, we will shed light on the interplay between autophagy and EVs in NASH, the emerging connection of EVs production with the autophagy pathway, and their possible manipulation for developing future therapeutic strategies for NASH.

Indexed as

Extracellular VesiclesNon-alcoholic Fatty Liver DiseaseAutophagyBiomarkersHumansLiverOxygenBiomarkersOxygenautophagyextracellular vesiclesliver injurynon-alcoholic fatty liver diseasenon-alcoholic steatohepatitissteatosis

Identifiers

PMID36293042
PMCPMC9603426
OpenAlexW4304807050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.